Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
TG Therapeutics, Inc.
National Cancer Institute (NCI)
Pharmacyclics LLC.